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DNA methylation primarily occurs within human cells as a 5-methylcytosine (5mC)
modification of the cytosine bases in CpG dinucleotides. 5mC has proven to be an
important epigenetic mark that is involved in the control of gene transcription for
processes such as development and differentiation. However, recent studies have
identified an alternative modification, 5-hydroxymethylcytosine (5hmC), which is formed
by oxidation of 5mC by ten-eleven translocation (TET) enzymes. The overall levels of
5hmC in the mammalian genome are approximately 10% of 5mC levels, although higher
levels have been detected in tissues of the central nervous system (CNS). The functions
of 5hmC are not yet fully known, but evidence suggests that 5hmC may be both an
intermediate product during the removal of 5mC by passive or active demethylation
processes and also an epigenetic modification in its own right, regulating chromatin or
transcriptional factors involved in processes such as neurodevelopment or environmental
stress response. This review highlights our current understanding of the role that 5hmC
plays in neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic
lateral sclerosis (ALS), fragile X-associated tremor/ataxia syndrome (FXTAS), Friedreich
ataxia (FRDA), Huntington’s disease (HD), and Parkinson’s disease (PD).
Keywords: 5-hydroxymethylcytosine, Alzheimer’s disease, amyotrophic lateral sclerosis, fragile X-associated
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INTRODUCTION
Methylation of mammalian DNA occurs by DNA methyltrans-
ferase (DNMT) enzymatic conversion of cytosine residues in CpG
dinucleotides to 5-methylcytosine (5mC) (Robertson, 2001).
CpG sites are clustered together as CpG islands (CGIs), which
locate to distinct gene regions, and the DNA methylation pro-
file of a gene has been shown to have a significant impact upon
its level of expression (Bird and Wolffe, 1999). Furthermore,
aberrant DNA methylation profiles are known to be associated
with many different human diseases, including Rett syndrome
(Amir et al., 1999) and cancer (Kulis and Esteller, 2010), where
there are alterations of global DNA methylation patterns, and
Fragile X syndrome (FXS), where there is specific methylation of
the CCG repeat mutation in the fragile X mental retardation-1
(FMR1) gene (Naumann et al., 2009). Abnormal global or local-
ized DNA methylation patterns have also been associated with
certain neurodegenerative diseases (Pook, 2012; Lu et al., 2013).
In 2009, two independent studies simultaneously
reported the existence of an alternative modification, 5-
hydroxymethylcytosine (5hmC), formed due to oxidation
of 5mC by ten-eleven translocation (TET) enzymes, a family of
2-oxoglutarate- and Fe(II)-dependent dioxygenases, consisting of
three proteins, TET1, TET2, and TET3 (Kriaucionis and Heintz,
2009; Tahiliani et al., 2009). Highly conserved homologous
proteins have also been identified in mouse, designated Tet1,
Tet2, and Tet3. Initial studies demonstrated roles for Tet enzymes,
converting 5mC to 5hmC, in pluripotency and developmental
reprogramming (Ito et al., 2010; Branco et al., 2011; Ficz et al.,
2011; Gu et al., 2011; Inoue and Zhang, 2011). Subsequent studies
in mouse embryonic stem (ES) cells suggested that Tet enzymes
could control DNA methylation both by the conversion of 5mC
to 5hmC and by binding to CpG rich regions to prevent DNMT
activity (Xu et al., 2011). More recently, outside of developmental
reprogramming, TET1 has been shown to act in differentiated
cells as a maintenance demethylase that prevents aberrant
methylation spreading into unmethylated or hypomethylated
CGIs (Jin et al., 2014). The overall levels of 5hmC in the mam-
malian genome have been reported to be approximately 10%
of 5mC levels (Branco et al., 2011), although higher levels have
been detected in tissues of the CNS (Globisch et al., 2010). For
example, 5hmC is approximately 40% as abundant as 5mC in the
DNA of Purkinje cells of the cerebellum (Kriaucionis and Heintz,
2009). Subsequent to the identification of 5hmC, two other
modifications of cytosine have been discovered, 5-formylcytosine
(5fC) and 5-carbamylcytosine (5caC). These are less abundant
than 5hmC and they are recognized as intermediates generated
by TET enzyme activity in the 5hmC to cytosine conversion
pathway (Ito et al., 2011).
Several research groups have studied the distribution of 5hmC
throughout the genome. In brain tissue, 5hmC is particularly
enriched within synaptic genes, exhibiting tissue-specific
differences at exon-intron boundaries, suggesting a potential
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role for 5hmC in the differential splicing of these genes (Khare
et al., 2012). Conversely, in human and mouse ES cells, 5hmC
is enriched at specific gene bodies, promoters and enhancers,
particularly at promoters marked with H3K4me3 andH3K27me3
and at enhancers marked with H3K4me1 and H3K27ac, suggest-
ing a role for 5hmC in the epigenetic regulation of transcription
(Pastor et al., 2011; Stroud et al., 2011; Szulwach et al., 2011a).
Furthermore, enrichment of 5hmC at both gene bodies of actively
transcribed genes and promoter regions of Polycomb-repressed
developmental regulator genes has provided evidence of a dual
role for 5hmC in pluripotent stem cells (Wu et al., 2011).
5hmC is also found in mitochondrial DNA (Iacobazzi et al.,
2013), which has implications for disorders of mitochondrial
dysfunction, including neurodegenerative diseases. Due to the
CNS-selective tissue distribution of 5hmC and its involvement
in epigenetic gene regulation during neurodevelopment, several
recent investigations have focused on uncovering potential roles
for 5hmC in neurodegenerative diseases. Here we summarize the
findings of this recent epigenetic-based neurological research.
THE FUNCTIONS OF 5hmC
Although the functions of 5hmC within the cell are not yet fully
known, evidence emerging from recent 5hmC protein binding
studies supports the existence of multiple roles (Figure 1).
Several proteins have now been shown to bind to 5hmC,
including UHRF1 (ubiquitin-like, containing PHD, and RING
finger domain 1) (Frauer et al., 2011), MBD3 (methyl-CpG
binding domain protein 3) (Yildirim et al., 2011), MeCP2
(methyl-CpG binding protein 2) (Mellen et al., 2012), UHRF2
(ubiquitin-like, containing PHD and RING finger domain 2)
and a number of other proteins identified by proteomics analysis
(Spruijt et al., 2013). These studies suggest that 5hmC is involved,
both indirectly and directly, in the dynamic interplay between
DNA methylation status and gene transcription.
Firstly, 5hmC acts as an intermediate in both the passive and
the active DNA demethylation conversion of 5mC to cytosine,
and thus is indirectly involved in regulating gene transcrip-
tion. Passive DNA demethylation occurs due to poor binding of
UHRF1 to 5hmC. Usually UHRF1 and its partner, DNMT1, act
together to bind to 5mC and carry out maintenance DNAmethy-
lation (Bostick et al., 2007). However, UHRF1 has a reduced bind-
ing affinity for 5hmC compared to 5mC (Frauer et al., 2011), and
therefore DNMT1may not be recruited tomaintain levels of DNA
methylation and hence passive demethylation occurs. Shortly
after the discovery that TET enzymes mediated the conversion of
5mC to 5hmC, other studies revealed that TET enzymes could
further oxidize 5hmC to 5fC and then 5caC (Ito et al., 2011).
This led to the understanding that active DNA demethylation can
occur through sequential stages of TET enzyme-mediated oxida-
tion, 5mC to 5hmC to 5fC to 5caC, followed by the action of
TDG to form an abasic site, which is then repaired to a cytosine
residue by BER activity (Guo et al., 2011; He et al., 2011; Maiti
and Drohat, 2011). An alternative active DNA demethylation
pathway that involves deamination of 5hmC to a hydroxyuracil
FIGURE 1 | Functions of 5hmC. 5hmC has several different functions that
impact upon gene transcription: (1) acting as an intermediate in passive DNA
demethylation due to poor binding between 5hmC and UHRF1, the partner of
DNMT1; (2) acting as an intermediate in TET/TDG/BER-based active DNA
methylation; (3) altering the ratio of 5mC-binding proteins (5mC-BPs) to
5hmC-binding proteins (5hmC-BPs) that impair or activate gene transcription.
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(5hmU) intermediate has also been proposed (Cortellino et al.,
2011). In addition, there is preliminary in vitro evidence that
the de novo DNA methyltransferases DNMT3A and DNMT3B
can act as DNA dehydroxymethylases, which may be able to
directly convert 5hmC to cytosine (Chen et al., 2012). Therefore,
changes in 5hmC status may simply reflect changes in the bio-
logical processes that require DNA demethylation, such as the
development of pre-implantation embryos or the reprogramming
of primordial germ cells (PGCs) (Kohli and Zhang, 2013). Global
DNA demethylation occurs during two stages of embryogene-
sis: (i) in zygotes where there is preferential DNA demethylation
of the parental genome, (ii) in PGCs during the establishment
of gender-specific DNA methylation patterns (Inoue and Zhang,
2011). Tet1 is not responsible for global demethylation in PGCs,
but has been shown to mediate locus-specific demethylation of
a subset of meiotic genes (Yamaguchi et al., 2012) and to have a
critical function in the erasure of genomic imprinting (Yamaguchi
et al., 2013).
Secondly, 5hmC binds chromatin regulator proteins, which
suggests that it is not merely an intermediate in DNA demethyla-
tion, but that it can more directly influence the regulation of gene
transcription in processes such as neurodevelopment (Szulwach
et al., 2011b) or cellular responses to oxidative stress (Chia et al.,
2011). For example, 5hmC may modulate the relative binding
of methyl-CpG-binding domain proteins, such as MeCP2 and
MBD3, to produce a more open chromatin state and activation
of gene transcription (Yildirim et al., 2011; Mellen et al., 2012).
Furthermore, 5hmC can be associated with, or affected by, par-
ticular histone modifications that influence gene transcription.
For example, tight correlations of 5hmC localization have been
reported with both histone H3K4me2, an epigenetic mark of
euchromatin, and H3K27me3, an epigenetic mark of heterochro-
matin, across a variety of somatic tissues (Haffner et al., 2013;
Chen et al., 2014). In addition, recent studies have shown that the
conversion of 5mC to 5hmC can be prevented by binding of PGC7
(also known as Dppa3 or Stella) to histone H3K9me2 (Nakamura
et al., 2012). Furthermore, as with 5hmC, it is possible that 5fC
and 5caC may also have independent functions in the regulation
of gene transcription (Raiber et al., 2012).
5hmC, NEURODEVELOPMENT AND NEURODEGENERATIVE
DISEASES
Several studies have suggested a role for 5hmC in the epige-
netic regulation of transcription, mediating brain development
and functional maintenance of the adult brain. At the outset,
comparatively high levels of 5hmC were detected in CNS tissues,
which contain predominantly non-proliferating cells (Globisch
et al., 2010). Thus, 5hmC was found to be approximately 40%
as abundant as 5mC in the DNA of Purkinje cells of the cerebel-
lum (Kriaucionis and Heintz, 2009). In contrast, loss of global
5hmC has been associated with cancer, suggesting that 5hmC
cannot be well maintained in highly proliferating cells (Pfeifer
et al., 2013). Throughout the stages of mouse neurodevelopment
from embryonic to adult brain, 5hmC has been shown to be not
merely an intermediate metabolite of DNA demethylation, but a
long-lasting but dynamic epigenetic mark that is distinct from
5mC. Thus, while 5mC differentially binds MBD1 and MeCP2,
and recruits H3K9me3 and H3K27me3, 5hmC progressively co-
localizes with MBD3 and recruits H3K4me2 (Chen et al., 2014).
Furthermore, a positive correlation has been reported between
5hmC levels and human cerebellum development (Wang et al.,
2012) and 5hmC has been reported to regulate transcriptional
factors involved in neurodevelopment (Szulwach et al., 2011b).
Finally, alterations of 5hmC have been implicated in a number
of neurodevelopmental diseases, including Rett syndrome, autism
spectrum disorders, schizophrenia and fetal alcohol syndrome
(Cheng et al., 2014).
Such growing evidence clearly indicates that 5hmC has an
important role to play in normal neurodevelopment and main-
tenance of adult CNS function. Thus, it is intuitive that abnor-
malities of 5hmC distribution or function may also be important
factors for neurodegenerative diseases. Indeed, a genome-wide
study of 5hmC distribution in mouse cerebellum has revealed
an age-related gene expression level-dependent enrichment of
5hmC in specific gene bodies that are linked to neurodegenerative
diseases in mice and humans, including ataxia and disorders of
Purkinje cell degeneration (Song et al., 2011b). The following sec-
tions describe the specific 5hmC studies that have been performed
in relation to individual neurodegenerative diseases.
AD
Alzheimer’s disease (AD) is the most common neurodegenera-
tive disorder, characterized by progressive decline of cognitive
functions, neuronal cell loss, and two hallmarks of pathology,
extracellular amyloid beta plaques and intracellular neurofib-
rillary tangles composed of hyperphosphorylated tau protein
(Tanzi, 2012). The causes of AD are unknown, but some evi-
dence has been gained from identifying abnormalities in selected
genes, including the beta-amyloid precursor protein gene, APP,
and the presenilin genes, PSEN1 and PSEN2. In addition, it
has been suggested that there may be alterations of epigenetic
factors due to aging or in response to environmental stresses
(Wang et al., 2008; Coppieters and Dragunow, 2011; Bihaqi et al.,
2012). Several studies have recently investigated the global lev-
els of DNA methylation-based enzymes and chromatin marks,
DNMT1, TET1, 5mC, 5hmC, 5fC, and 5caC, in AD brain tis-
sues using a variety of immunohistochemical detection methods,
with somewhat contradictory results (Table 1). Initial studies of
human brain samples, specifically the entorhinal cortex layer II
of the medial temporal lobe, revealed evidence of decreased lev-
els of 5mC and DNMT1 in neurons of AD patients (Mastroeni
et al., 2010). Similar decreases in 5mC, together with decreased
levels of 5hmC, were subsequently identified in the hippocampal
region of AD brains (Chouliaras et al., 2013). However, fur-
ther studies have shown exactly the opposite effects, reporting
increased levels of both 5mC and 5hmC in AD brains (Table 1).
Firstly, increased levels of 5mC have been detected in frontal cor-
tex of AD patients (Rao et al., 2012). Secondly, increased levels
of TET1, 5mC, and 5hmC, accompanied by decreases in the lev-
els of 5fC and 5caC, have been detected in the hippocampus
of AD patients, while no changes were detected in cerebellum
tissues (Bradley-Whitman and Lovell, 2013). Finally, increased
levels of both 5mC and 5hmC have been detected in the frontal
and temporal cortex of AD patients (Coppieters et al., 2014).
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The reasons for the discrepancies between the different studies
will require further investigation, but they may be due to the
analysis of different regions of the brain and the use of different
immunohistochemical quantification techniques. It will also be
interesting to investigate levels of locus-specific 5hmC at specific
genes related to AD pathology, such as the APP and PSEN1 genes,
which have previously shown AD-related changes in 5mC levels
(Rogaev et al., 1994; Tohgi et al., 1999; Barrachina and Ferrer,
2009). Only after such studies will the role of 5hmC in either the
causes or consequences of AD pathogenesis become apparent.
ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegen-
erative disease characterized by selective loss of motor neurons
within the brain and spinal cord (Calvo et al., 2014). The cause
of ALS is largely unknown, although defective genes have been
identified in a small percentage of familial ALS cases, including
those encoding superoxide dismutase 1 (SOD1), TAR DNA-
Binding Protein (TARDBP), fused in sarcoma (FUS), Ubiquilin2
(UBQLN2) and C9ORF72 (Chen et al., 2013). For the much
larger percentage of sporadic ALS cases, it has been suggested
that environmental factors, such as exposure to toxins or dietary
factors, may be driving more global epigenetic changes (Ahmed
and Wicklund, 2011). Therefore, it is interesting to note that one
recent study has reported global increases in both 5mC and 5hmC
levels in postmortem sporadic ALS spinal cord, but not in blood
samples (Figueroa-Romero et al., 2012) (Table 1). The differences
between spinal cord and blood samples suggest that neither 5mC
nor 5hmC would currently be suitable as biomarkers of ALS, but
further studies will no doubt follow to shed further light onto the
role of 5hmC in ALS.
FXTAS
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-
onset neurodegenerative disease caused by CGG repeat expansion
mutations within the 5′ untranslated region (UTR) of the FMR1
gene (Hagerman et al., 2001). FXTAS patients carry 55–200 CGG
repeats, regarded as premutation alleles, and although they do
not exhibit signs of disease in early life, they generally develop
severe tremor, ataxia and progressive cognitive decline in the
fifth decades of life. In contrast, individuals who carry over 200
CGG repeats, regarded as full mutations, develop FXS, which
is the commonest form of inherited mental retardation (Bagni
and Oostra, 2013). In FXS, the CGG repeat expansion muta-
tion becomes hyermethylated, as does the CpG island within the
FMR1 promoter region, resulting in reduced expression of FMR1
(Naumann et al., 2009). However, in FXTAS there is increased
expression of FMR1, and a toxic RNA gain of function is con-
sidered to be the primary disease mechanism (Jacquemont et al.,
2003; Jin et al., 2003). To the best of our knowledge, there have
not yet been any reports describing the levels of 5hmC at the
FMR1 locus in either FXS or FXTAS. However, one study has
investigated global levels of 5hmC in the rCGG mouse model
of FXTAS, which is characterized by overexpression of human
CGG repeats within the 5 UTR of the FMR1 gene in Purkinje
neuronal cells, leading to cell death and subsequent behavioral
deficits (Hashem et al., 2009). The results showed there to be a
genome-wide decrease in 5hmC levels in the cerebellum tissues
of rCGG mice compared with age-matched wild-type controls,
mainly within gene bodies and CGIs (Yao et al., 2014). However,
there were also increases of 5hmC levels in repetitive elements
and cerebellum-specific enhancers that correlated with genes and
transcription factors known to be involved in neurodevelopment
Table 1 | Alterations of 5hmC in neurodegenerative diseases.
Disease 5hmC effect Other epigenetic effects References
AD Not tested Decreased global DNMT1 and 5mC in AD temporal
cortex
Mastroeni et al., 2010
Decreased global 5hmC in AD hippocampus Decreased global 5mC in AD hippocampus Chouliaras et al., 2013
Not tested Increased global 5mC in AD frontal cortex Rao et al., 2012
Increased global 5hmC in AD hippocampus, but no
change in cerebellum
Increased global Tet1 and 5mC, and decreased
global 5fC and 5caC in AD hippocampus, but no
change in cerebellum
Bradley-Whitman and Lovell,
2013
Increased global 5hmC in AD frontal and temporal
cortex
Increased global 5mC in AD frontal and temporal
cortex
Coppieters et al., 2014
ALS Increased global 5hmC in sporadic ALS spinal cord Increased global 5mC in sporadic ALS spinal cord Figueroa-Romero et al., 2012
FXTAS Decreased global 5hmC in rCGG FXTAS mouse
model cerebellum
Yao et al., 2014
FRDA Increased 5hmC at the 5’ GAA repeat region of the
FXN gene in FRDA cerebellum and heart
Increased 5mC at the 5’ GAA repeat region and
decreased 5mC at the 3’ GAA repeat region of the
FXN gene in FRDA cerebellum and heart
Al-Mahdawi et al., 2008, 2013
HD Decreased 5hmC in the ADORA2A gene in HD
putamen
Increased 5mC in the ADORA2A gene in HD
putamen
Villar-Menendez et al., 2013
Decreased global 5hmC in YAC128 HD mouse
model striatum and cortex
Wang et al., 2013
PD No change in 5hmC in 6-OHDA PD rat model
striatum
Zhang et al., 2013
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(Table 1). These findings strongly suggest a potential function for
5hmC as part of the disease mechanism for FXTAS.
FRDA
Friedreich ataxia (FRDA) is a rare autosomal recessive neurode-
generative disorder caused by GAA repeat expansion mutation
within intron 1 of the FXN gene, leading to decreased expres-
sion of the essential mitochondrial protein frataxin (Campuzano
et al., 1996). The main sites of pathology are the large sensory
neurons of the dorsal root ganglia and the dentate nucleus of
the cerebellum (Koeppen, 2013), although non-CNS patholo-
gies are also evident, including hypertrophic cardiomyopathy
(Weidemann et al., 2013) and diabetes (Cnop et al., 2013). Several
studies have identified FRDA-related epigenetic changes, includ-
ing alterations of DNA methylation status, in the immediate
vicinity of the expanded GAA repeats of the FXN gene (Evans-
Galea et al., 2013; Sandi et al., 2014). An initial investigation of
DNAmethylation revealed hypermethylation of specific CpG sites
upstream of the GAA repeat in FRDA patient lymphoblastoid
cells compared to unaffected controls (Greene et al., 2007). Our
group subsequently identified hypermethylation at the upstream
GAA repeat region in FRDA postmortem cerebellum and heart
tissues (Al-Mahdawi et al., 2008). Interestingly, we also identi-
fied reduced hypomethylation in the downstream GAA repeat
region in FRDA patient tissues compared with controls. These
findings were confirmed in blood and buccal cell samples from
a large cohort of FRDA patients, where a significant inverse corre-
lation was also detected between the level of DNA methylation
in the upstream GAA region and the level of FXN expression
(Evans-Galea et al., 2012). Yet another study has shown that the
degree of DNA methylation in the upstream GAA repeat region
in FRDA patients correlates with the length of the GAA repeats
and inversely correlates with the age of disease onset (Castaldo
et al., 2008). Therefore, there is good evidence that DNA methy-
lation may have an, as yet unknown, role to play in the molecular
mechanism of FRDA. With this in mind, our group have recently
analyzed the 5hmC status of one of the FXN upstream GAA CpG
sites in FRDA cerebellum and heart tissues using a restriction
enzyme-based procedure that allowed distinction between 5hmC
and 5mC and we found that the majority of the hypermethylated
DNA at this CpG residue comprises 5hmC rather than 5mC (Al-
Mahdawi et al., 2013) (Table 1). It is possible that raised 5hmC
levels reflect an attempt to reverse GAA repeat-induced FXN gene
silencing, which is marked by increased DNA methylation at the
upstream GAA repeat region, rather than indicating any involve-
ment in the cause of disease. Therefore, it will be interesting to see
if there are further 5hmC alterations of the FXN gene, or indeed
other genes, associated with FRDA.
HD
Huntington’s disease (HD) is an autosomal dominant progres-
sive neurodegenerative disease, characterized by chorea, dystonia,
and cognitive decline, with the main site of pathology being
the striatum. HD is caused by CAG repeat expansion mutation
within exon 1 of the HTT gene, leading to abnormal polyglu-
tamine formation within the amino-terminus of the HTT protein
(MacDonald et al., 2003). The mechanism of disease is unknown,
although many studies have provided evidence for polyglutamine
or RNA toxic gains of function as well as haploinsufficiency or
alternative splicing of the HTT gene as potential causes (Landles
and Bates, 2004; Sathasivam et al., 2013). More recently, evi-
dence has been put forward from two studies to suggest the
potential involvement of 5hmC in HD by two distinct mecha-
nisms (Table 1). Firstly, increased levels of 5mC and decreased
levels of 5hmC were identified in the 5′ UTR of the ADORA2A
gene in the striatum (specifically the putamen) of HD patients
compared with age-matched controls (Villar-Menendez et al.,
2013). The ADORA2A gene encodes the adenosine A2A receptor,
a G-protein-coupled receptor that is normally highly expressed
in the basal ganglia, but severely reduced in HD (Glass et al.,
2000). Secondly, genome-wide loss of 5hmC has been reported in
YAC128 HD mouse striatum and cortex brain tissues compared
with age-matched wild-type controls (Wang et al., 2013). A closer
inspection of this data revealed 747 differentially hydroxymethy-
lated regions in the striatum of which 49 showed HD-related
increases of 5hmC, enriched in gene bodies and positively cor-
related with gene transcription, and 698 showed HD-related
decreases of 5hmC. The authors speculate that 5hmC is a novel
epigenetic feature in HD, involved in neurogenesis, neuronal
function and survival in HD brain.
PD
Parkinson’s disease (PD) is the second most common neurode-
generative disease after AD, characterized by the progressive loss
of substantia nigra dopaminergic neurons, resulting in mus-
cle rigidity, bradykinesia, tremor, and instability. The causes of
PD are unknown, but mutations in several genes have now
been identified in rare cases of inherited PD, including the
genes SNCA (alpha-synuclein), PARK2 (parkin), PTEN induced
Putative Kinase 1 (PINK1), PARK7 (DJ-1), Leucine Rich Repeat
Kinase 2 (LRRK2) and ATP13A2 (Yang et al., 2009). Previous
studies have suggested the potential involvement of DNA methy-
lation in PD, particularly with regards to regulation of SNCA gene
expression, but without solid conclusions (Lu et al., 2013). More
recently, 5hmC levels have been studied in striatal brain tissues
of the 6-OHDA induced rat model of PD, but while 5hmC con-
tent generally increased with age, no changes in 5hmC levels were
detected compared with controls (Zhang et al., 2013). Therefore,
any potential involvement of 5hmC in the causes or consequences
of PD remain to be identified.
CONCLUSIONS: IMPLICATIONS FOR DIAGNOSIS AND
THERAPY OF NEURODEGENERATIVE DISEASES
To date, the investigations of 5hmC in relation to neurodegener-
ative diseases can be considered to be within their early days. Of
the few studies that have been performed, no common features
have emerged regarding 5hmC alterations and neurodegenerative
diseases; both global increases and decreases of 5hmC levels have
been identified in different diseases, and in the case of AD, within
the same disease. It is likely that poorly reproducible techniques
of immunohistochemical quantification have contributed to this
lack of clarity. One impetus behind the recent studies of 5hmC is
the potential to identify changes in 5hmC as a potential biomarker
of neurodegenerative disease. Alterations of 5hmC levels may be
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useful, irrespective of whether they are considered to be a cause
or a consequence of the disease process. However, initial studies
of sporadic ALS have revealed no correlation between alterations
of 5hmC, or indeed in 5mC, in spinal cord and blood, suggesting
that these would not be suitable as biomarkers of this neurode-
generative disease (Figueroa-Romero et al., 2012). Another driver
behind 5hmC studies of neurodegenerative disease is the poten-
tial to identify novel targets for therapy. In this case, alterations
of 5hmC levels would have to be involved in the molecular dis-
ease process rather than being a consequence of disease. However,
if 5hmC does indeed prove to be a significant epigenetic mark
involved in the causation of neurodegenerative disease, then it
may be possible to develop drugs that modify the 5hmC sta-
tus, either to decrease 5hmC levels by inhibition of TET enzyme
activity (Xiao et al., 2012) or to increase 5hmC levels by enhance-
ment of TET enzyme activity (Yin et al., 2013). However, further
investigations of 5hmC alterations are first required for all neu-
rodegenerative diseases, both at global and locus-specific levels.
Such studies will be enhanced by the development of state of the
art technologies, such as the recently described third-generation
sequencing and oxidative bisulfite (oxBs) BeadChip platforms
(Song et al., 2011a; Stewart et al., 2014).
AUTHOR CONTRIBUTIONS
All authors contributed to draft the manuscript and all authors
read and approved the final manuscript.
ACKNOWLEDGMENTS
Sara Anjomani Virmouni was supported by funding to Mark A.
Pook from the Friedreich’s Ataxia Research Alliance (FARA).
REFERENCES
Ahmed, A., and Wicklund, M. P. (2011). Amyotrophic lateral sclero-
sis: what role does environment play? Neurol. Clin. 29, 689–711. doi:
10.1016/j.ncl.2011.06.001
Al-Mahdawi, S., Pinto, R. M., Ismail, O., Varshney, D., Lymperi, S., Sandi, C., et al.
(2008). The Friedreich ataxia GAA repeat expansion mutation induces com-
parable epigenetic changes in human and transgenic mouse brain and heart
tissues. Hum. Mol. Genet. 17, 735–746. doi: 10.1093/hmg/ddm346
Al-Mahdawi, S., Sandi, C., Mouro Pinto, R., and Pook, M. A. (2013). Friedreich
ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification
and decreased CTCF binding at the FXN locus. PLoS ONE 8:e74956. doi:
10.1371/journal.pone.0074956
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., and Zoghbi,
H. Y. (1999). Rett syndrome is caused by mutations in X-linkedMECP2, encod-
ing methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188. doi: 10.1038/
13810
Bagni, C., and Oostra, B. A. (2013). Fragile X syndrome: from protein func-
tion to therapy. Am. J. Med. Genet. A 161A, 2809–2821. doi: 10.1002/ajmg.a.
36241
Barrachina, M., and Ferrer, I. (2009). DNA methylation of Alzheimer disease and
tauopathy-related genes in postmortem brain. J. Neuropathol. Exp. Neurol. 68,
880–891. doi: 10.1097/NEN.0b013e3181af2e46
Bihaqi, S. W., Schumacher, A., Maloney, B., Lahiri, D. K., and Zawia, N. H. (2012).
Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards
a new paradigm. Curr. Alzheimer Res. 9, 574–588. doi: 10.2174/156720512800
617982
Bird, A. P., and Wolffe, A. P. (1999). Methylation-induced repression–belts, braces,
and chromatin. Cell 99, 451–454 doi: 10.1016/S0092-8674(00)81532-9
Bostick, M., Kim, J. K., Esteve, P. O., Clark, A., Pradhan, S., and Jacobsen, S. E.
(2007). UHRF1 plays a role in maintaining DNA methylation in mammalian
cells. Science 317, 1760–1764. doi: 10.1126/science.1147939
Bradley-Whitman, M. A., and Lovell, M. A. (2013). Epigenetic changes in the
progression of Alzheimer’s disease. Mech. Ageing Dev. 134, 486–495. doi:
10.1016/j.mad.2013.08.005
Branco, M. R., Ficz, G., and Reik, W. (2011). Uncovering the role of 5-
hydroxymethylcytosine in the epigenome. Nat. Rev. Genet. 13, 7–13. doi: 10.
1038/nrg3080
Calvo, A. C., Manzano, R., Mendonca, D. M., Munoz, M. J., Zaragoza, P., and Osta,
R. (2014). Amyotrophic lateral sclerosis: a focus on disease progression. Biomed
Res. Int. 2014:925101. doi: 10.1155/2014/925101
Campuzano, V., Montermini, L., Molto, M. D., Pianese, L., Cossee, M., Cavalcanti,
F., et al. (1996). Friedreich’s ataxia: autosomal recessive disease caused by an
intronic GAA triplet repeat expansion. Science 271, 1423–1427 doi: 10.1126/sci-
ence.271.5254.1423
Castaldo, I., Pinelli, M., Monticelli, A., Acquaviva, F., Giacchetti, M., Filla, A., et al.
(2008). DNA methylation in intron 1 of the frataxin gene is related to GAA
repeat length and age of onset in Friedreich ataxia patients. J. Med. Genet. 45,
808–812. doi: 10.1136/jmg.2008.058594
Chen, C. C., Wang, K. Y., and Shen, C. K. (2012). The mammalian de
novo DNA methyltransferases DNMT3A and DNMT3B are also DNA 5-
hydroxymethylcytosine dehydroxymethylases. J. Biol. Chem. 287, 33116–33121.
doi: 10.1074/jbc.C112.406975
Chen, S., Sayana, P., Zhang, X., and Le, W. (2013). Genetics of amyotrophic lateral
sclerosis: an update. Mol. Neurodegener. 8:28. doi: 10.1186/1750-1326-8-28
Chen, Y., Damayanti, N. P., Irudayaraj, J., Dunn, K., and Zhou, F. C. (2014).
Diversity of two forms of DNA methylation in the brain. Front. Genet. 5:46.
doi: 10.3389/fgene.2014.00046
Cheng, Y., Bernstein, A., Chen, D., and Jin, P. (2014). 5-hydroxymethylcytosine:
a new player in brain disorders? Exp. Neurol. doi: 10.1016/j.expneurol.2014.
05.008. [Epub ahead of print].
Chia, N., Wang, L., Lu, X., Senut, M. C., Brenner, C., and Ruden, D. M. (2011).
Hypothesis: environmental regulation of 5-hydroxymethylcytosine by oxidative
stress. Epigenetics 6, 853–856. doi: 10.4161/epi.6.7.16461
Chouliaras, L., Mastroeni, D., Delvaux, E., Grover, A., Kenis, G., Hof, P. R., et al.
(2013). Consistent decrease in global DNA methylation and hydroxymethyla-
tion in the hippocampus of Alzheimer’s disease patients. Neurobiol. Aging 34,
2091–2099. doi: 10.1016/j.neurobiolaging.2013.02.021
Cnop, M., Mulder, H., and Igoillo-Esteve, M. (2013). Diabetes in Friedreich ataxia.
J. Neurochem. 126(Suppl. 1), 94–102. doi: 10.1111/jnc.12216
Coppieters, N., Dieriks, B. V., Lill, C., Faull, R. L., Curtis, M. A., and Dragunow,
M. (2014). Global changes in DNA methylation and hydroxymethylation
in Alzheimer’s disease human brain. Neurobiol. Aging 35, 1334–1344. doi:
10.1016/j.neurobiolaging.2013.11.031
Coppieters, N., and Dragunow, M. (2011). Epigenetics in Alzheimer’s disease: a
focus on DNA modifications. Curr. Pharm. Des. 17, 3398–3412. doi: 10.2174/
138161211798072544
Cortellino, S., Xu, J., Sannai, M., Moore, R., Caretti, E., Cigliano, A., et al. (2011).
Thymine DNA glycosylase is essential for active DNA demethylation by linked
deamination-base excision repair. Cell 146, 67–79. doi: 10.1016/j.cell.2011.
06.020
Evans-Galea, M. V., Carrodus, N., Rowley, S. M., Corben, L. A., Tai, G., Saffery,
R., et al. (2012). FXN methylation predicts expression and clinical outcome in
Friedreich ataxia. Ann. Neurol. 71, 487–497. doi: 10.1002/ana.22671
Evans-Galea, M. V., Hannan, A. J., Carrodus, N., Delatycki, M. B., and Saffery, R.
(2013). Epigenetic modifications in trinucleotide repeat diseases. Trends Mol.
Med. 19, 655–663. doi: 10.1016/j.molmed.2013.07.007
Ficz, G., Branco, M. R., Seisenberger, S., Santos, F., Krueger, F., Hore, T. A.,
et al. (2011). Dynamic regulation of 5-hydroxymethylcytosine in mouse ES
cells and during differentiation. Nature 473, 398–402. doi: 10.1038/nature
10008
Figueroa-Romero, C., Hur, J., Bender, D. E., Delaney, C. E., Cataldo, M. D.,
Smith, A. L., et al. (2012). Identification of epigenetically altered genes in
sporadic amyotrophic lateral sclerosis. PLoS ONE 7:e52672. doi: 10.1371/jour-
nal.pone.0052672
Frauer, C., Hoffmann, T., Bultmann, S., Casa, V., Cardoso, M. C., Antes, I., et al.
(2011). Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain.
PLoS ONE 6:e21306. doi: 10.1371/journal.pone.0021306
Glass, M., Dragunow, M., and Faull, R. L. (2000). The pattern of neurode-
generation in Huntington’s disease: a comparative study of cannabinoid,
dopamine, adenosine and GABA(A) receptor alterations in the human basal
Frontiers in Neuroscience | Neurogenomics December 2014 | Volume 8 | Article 397 | 6
Al-Mahdawi et al. 5hmC and neurodegenerative diseases
ganglia in Huntington’s disease. Neuroscience 97, 505–519. doi: 10.1016/S0306-
4522(00)00008-7
Globisch, D., Munzel, M., Muller, M., Michalakis, S., Wagner, M., Koch, S.,
et al. (2010). Tissue distribution of 5-hydroxymethylcytosine and search for
active demethylation intermediates. PLoS ONE 5:e15367. doi: 10.1371/jour-
nal.pone.0015367
Greene, E., Mahishi, L., Entezam, A., Kumari, D., and Usdin, K. (2007). Repeat-
induced epigenetic changes in intron 1 of the frataxin gene and its conse-
quences in Friedreich ataxia.Nucleic Acids Res. 35, 3383–3390. doi: 10.1093/nar/
gkm271
Gu, T. P., Guo, F., Yang, H., Wu, H. P., Xu, G. F., Liu, W., et al. (2011). The role
of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 477,
606–610. doi: 10.1038/nature10443
Guo, J. U., Su, Y., Zhong, C., Ming, G. L., and Song, H. (2011). Hydroxylation of 5-
methylcytosine by TET1 promotes active DNA demethylation in the adult brain.
Cell 145, 423–434. doi: 10.1016/j.cell.2011.03.022
Haffner, M. C., Pellakuru, L. G., Ghosh, S., Lotan, T. L., Nelson,W. G., DeMarzo, A.
M., et al. (2013). Tight correlation of 5-hydroxymethylcytosine and Polycomb
marks in health and disease. Cell Cycle 12, 1835–1841. doi: 10.4161/cc.25010
Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., et al.
(2001). Intention tremor, parkinsonism, and generalized brain atrophy in male
carriers of fragile X. Neurology 57, 127–130 doi: 10.1212/WNL.57.1.127
Hashem, V., Galloway, J. N., Mori, M., Willemsen, R., Oostra, B. A., Paylor, R.,
et al. (2009). Ectopic expression of CGG containing mRNA is neurotoxic in
mammals. Hum. Mol. Genet. 18, 2443–2451. doi: 10.1093/hmg/ddp182
He, Y. F., Li, B. Z., Li, Z., Liu, P., Wang, Y., Tang, Q., et al. (2011). Tet-mediated
formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.
Science 333, 1303–1307. doi: 10.1126/science.1210944
Iacobazzi, V., Castegna, A., Infantino, V., and Andria, G. (2013). Mitochondrial
DNA methylation as a next-generation biomarker and diagnostic tool. Mol.
Genet. Metab. 110, 25–34. doi: 10.1016/j.ymgme.2013.07.012
Inoue, A., and Zhang, Y. (2011). Replication-dependent loss of 5-
hydroxymethylcytosine in mouse preimplantation embryos. Science 334,
194. doi: 10.1126/science.1212483
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., and Zhang, Y.
(2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal
and inner cell mass specification. Nature 466, 1129–1133. doi: 10.1038/nature
09303
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., et al.
(2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and
5-carboxylcytosine. Science 333, 1300–1303. doi: 10.1126/science.1210597
Jacquemont, S., Hagerman, R. J., Leehey, M., Grigsby, J., Zhang, L., Brunberg, J.
A., et al. (2003). Fragile X premutation tremor/ataxia syndrome: molecular,
clinical, and neuroimaging correlates. Am. J. Hum. Genet. 72, 869–878. doi:
10.1086/374321
Jin, C., Lu, Y., Jelinek, J., Liang, S., Estecio, M. R., Barton, M. C., et al. (2014).
TET1 is a maintenance DNA demethylase that prevents methylation spreading
in differentiated cells.Nucleic Acids Res. 42, 6956–6971. doi: 10.1093/nar/gku372
Jin, P., Zarnescu, D. C., Zhang, F., Pearson, C. E., Lucchesi, J. C., Moses, K., et al.
(2003). RNA-mediated neurodegeneration caused by the fragile X premuta-
tion rCGG repeats in Drosophila. Neuron 39, 739–747. doi: 10.1016/S0896-
6273(03)00533-6
Khare, T., Pai, S., Koncevicius, K., Pal, M., Kriukiene, E., Liutkeviciute, Z., et al.
(2012). 5-hmC in the brain is abundant in synaptic genes and shows differ-
ences at the exon-intron boundary. Nat. Struct. Mol. Biol. 19, 1037–1043. doi:
10.1038/nsmb.2372
Koeppen, A. H. (2013). Nikolaus Friedreich and degenerative atrophy of the
dorsal columns of the spinal cord. J. Neurochem. 126(Suppl. 1), 4. doi:
10.1111/jnc.12218
Kohli, R. M., and Zhang, Y. (2013). TET enzymes, TDG and the dynamics of DNA
demethylation. Nature 502, 472–479. doi: 10.1038/nature12750
Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-
hydroxymethylcytosine is present in Purkinje neurons and the brain. Science
324, 929–930. doi: 10.1126/science.1169786
Kulis, M., and Esteller, M. (2010). DNA methylation and cancer. Adv. Genet. 70,
27–56. doi: 10.1016/B978-0-12-380866-0.60002-2
Landles, C., and Bates, G. P. (2004). Huntingtin and the molecular pathogenesis of
Huntington’s disease. Fourth in molecular medicine review series. EMBO Rep.
5, 958–963. doi: 10.1038/sj.embor.7400250
Lu, H., Liu, X., Deng, Y., and Qing, H. (2013). DNA methylation, a
hand behind neurodegenerative diseases. Front. Aging Neurosci. 5:85. doi:
10.3389/fnagi.2013.00085
MacDonald, M. E., Gines, S., Gusella, J. F., andWheeler, V. C. (2003). Huntington’s
disease. Neuromolecular Med. 4, 7–20. doi: 10.1385/NMM:4:1-2:7
Maiti, A., and Drohat, A. C. (2011). Thymine DNA glycosylase can rapidly excise
5-formylcytosine and 5-carboxylcytosine: potential implications for active
demethylation of CpG sites. J. Biol. Chem. 286, 35334–35338. doi: 10.1074/jbc.
C111.284620
Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., and Rogers, J.
(2010). Epigenetic changes in Alzheimer’s disease: decrements in DNA methy-
lation. Neurobiol. Aging 31, 2025–2037. doi: 10.1016/j.neurobiolaging.2008.
12.005
Mellen, M., Ayata, P., Dewell, S., Kriaucionis, S., and Heintz, N. (2012). MeCP2
binds to 5hmC enriched within active genes and accessible chromatin in the
nervous system. Cell 151, 1417–1430. doi: 10.1016/j.cell.2012.11.022
Nakamura, T., Liu, Y. J., Nakashima, H., Umehara, H., Inoue, K., Matoba, S., et al.
(2012). PGC7 binds histone H3K9me2 to protect against conversion of 5mC to
5hmC in early embryos. Nature 486, 415–419. doi: 10.1038/nature11093
Naumann, A., Hochstein, N., Weber, S., Fanning, E., and Doerfler, W. (2009). A
distinct DNA-methylation boundary in the 5’- upstream sequence of the FMR1
promoter binds nuclear proteins and is lost in fragile X syndrome. Am. J. Hum.
Genet. 85, 606–616. doi: 10.1016/j.ajhg.2009.09.018
Pastor, W. A., Pape, U. J., Huang, Y., Henderson, H. R., Lister, R., Ko, M., et al.
(2011). Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem
cells. Nature 473, 394–397. doi: 10.1038/nature10102
Pfeifer, G. P., Kadam, S., and Jin, S. G. (2013). 5-hydroxymethylcytosine and its
potential roles in development and cancer. Epigenetics Chromatin. 6:10. doi: 10.
1186/1756-8935-6-10
Pook, M. A. (2012). “DNA methylation and trinucleotide repeat expansion dis-
eases,” in DNA Methylation - From Genomics to Technology, ed T. Tatarinova
(InTech). doi: 10.5772/34169
Raiber, E. A., Beraldi, D., Ficz, G., Burgess, H. E., Branco, M. R., Murat, P., et al.
(2012). Genome-wide distribution of 5-formylcytosine in embryonic stem cells
is associated with transcription and depends on thymine DNA glycosylase.
Genome Biol. 13:R69. doi: 10.1186/gb-2012-13-8-r69
Rao, J. S., Keleshian, V. L., Klein, S., and Rapoport, S. I. (2012). Epigenetic modifi-
cations in frontal cortex from Alzheimer’s disease and bipolar disorder patients.
Transl. Psychiatry 2, e132. doi: 10.1038/tp.2012.55
Robertson, K. D. (2001). DNA methylation, methyltransferases, and cancer.
Oncogene 20, 3139–3155. doi: 10.1038/sj.onc.1204341
Rogaev, E. I., Lukiw,W. J., Lavrushina, O., Rogaeva, E. A., and St. George-Hyslop, P.
H. (1994). The upstream promoter of the beta-amyloid precursor protein gene
(APP) shows differential patterns of methylation in human brain. Genomics 22,
340–347. doi: 10.1006/geno.1994.1393
Sandi, C., Sandi, M., Anjomani Virmouni, S., Al-Mahdawi, S., and Pook, M. A.
(2014). Epigenetic-based therapies for Friedreich ataxia. Front. Genet. 5:165.
doi: 10.3389/fgene.2014.00165
Sathasivam, K., Neueder, A., Gipson, T. A., Landles, C., Benjamin, A. C., Bondulich,
M. K., et al. (2013). Aberrant splicing of HTT generates the pathogenic exon 1
protein in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 110, 2366–2370. doi:
10.1073/pnas.1221891110
Song, C. X., Clark, T. A., Lu, X. Y., Kislyuk, A., Dai, Q., Turner, S. W., et al. (2011a).
Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine.
Nat. Methods 9, 75–77. doi: 10.1038/nmeth.1779
Song, C. X., Szulwach, K. E., Fu, Y., Dai, Q., Yi, C., Li, X., et al. (2011b).
Selective chemical labeling reveals the genome-wide distribution of 5-
hydroxymethylcytosine. Nat. Biotechnol. 29, 68–72. doi: 10.1038/nbt.1732
Spruijt, C. G., Gnerlich, F., Smits, A. H., Pfaffeneder, T., Jansen, P. W., Bauer, C.,
et al. (2013). Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized
derivatives. Cell 152, 1146–1159. doi: 10.1016/j.cell.2013.02.004
Stewart, S. K., Morris, T. J., Guilhamon, P., Bulstrode, H., Bachman, M.,
Balasubramanian, S., et al. (2014). oxBS-450K: a method for analysing hydrox-
ymethylation using 450K BeadChips. Methods. doi: 10.1016/j.ymeth.2014.
08.009. [Epub ahead of print].
Stroud, H., Feng, S., Morey Kinney, S., Pradhan, S., and Jacobsen, S. E. (2011).
5-Hydroxymethylcytosine is associated with enhancers and gene bodies in
human embryonic stem cells. Genome Biol. 12:R54. doi: 10.1186/gb-2011-12-
6-r54
www.frontiersin.org December 2014 | Volume 8 | Article 397 | 7
Al-Mahdawi et al. 5hmC and neurodegenerative diseases
Szulwach, K. E., Li, X., Li, Y., Song, C. X., Han, J. W., Kim, S., et al.
(2011a). Integrating 5-hydroxymethylcytosine into the epigenomic landscape
of human embryonic stem cells. PLoS Genet. 7:e1002154. doi: 10.1371/jour-
nal.pgen.1002154
Szulwach, K. E., Li, X., Li, Y., Song, C. X., Wu, H., Dai, Q., et al. (2011b). 5-hmC-
mediated epigenetic dynamics during postnatal neurodevelopment and aging.
Nat. Neurosci. 14, 1607–1616. doi: 10.1038/nn.2959
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y.,
et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalianDNA byMLL partner TET1. Science 324, 930–935. doi: 10.1126/sci-
ence.1170116
Tanzi, R. E. (2012). The genetics of Alzheimer disease. Cold Spring Harb. Perspect.
Med. 2, 1–10. doi: 10.1101/cshperspect.a006296
Tohgi, H., Utsugisawa, K., Nagane, Y., Yoshimura, M., Genda, Y., and Ukitsu, M.
(1999). Reduction with age in methylcytosine in the promoter region -224
approximately -101 of the amyloid precursor protein gene in autopsy human
cortex. Brain Res. Mol. Brain Res. 70, 288–292. doi: 10.1016/S0169-328X(99)
00163-1
Villar-Menendez, I., Blanch, M., Tyebji, S., Pereira-Veiga, T., Albasanz, J. L.,
Martin, M., et al. (2013). Increased 5-methylcytosine and decreased 5-
hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in
Huntington’s disease. Neuromolecular Med. 15, 295–309. doi: 10.1007/s12017-
013-8219-0
Wang, F., Yang, Y., Lin, X., Wang, J. Q., Wu, Y. S., Xie, W., et al. (2013). Genome-
wide loss of 5-hmC is a novel epigenetic feature of Huntington’s disease. Hum.
Mol. Genet. 22, 3641–3653. doi: 10.1093/hmg/ddt214
Wang, S. C., Oelze, B., and Schumacher, A. (2008). Age-specific epigenetic
drift in late-onset Alzheimer’s disease. PLoS ONE 3:e2698. doi: 10.1371/jour-
nal.pone.0002698
Wang, T., Pan, Q., Lin, L., Szulwach, K. E., Song, C. X., He, C., et al. (2012).
Genome-wide DNA hydroxymethylation changes are associated with neurode-
velopmental genes in the developing human cerebellum. Hum. Mol. Genet. 21,
5500–5510. doi: 10.1093/hmg/dds394
Weidemann, F., Stork, S., Liu, D., Hu, K., Herrmann, S., Ertl, G., et al. (2013).
Cardiomyopathy of Friedreich ataxia. J. Neurochem. 126(Suppl. 1), 88–93. doi:
10.1111/jnc.12217
Wu, H., D’Alessio, A. C., Ito, S., Wang, Z., Cui, K., Zhao, K., et al. (2011). Genome-
wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function
in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 25,
679–684. doi: 10.1101/gad.2036011
Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., et al. (2012).
Inhibition of alpha-KG-dependent histone and DNA demethylases by
fumarate and succinate that are accumulated in mutations of FH and
SDH tumor suppressors. Genes Dev. 26, 1326–1338. doi: 10.1101/gad.1910
56.112
Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., et al. (2011). Genome-wide
regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse
embryonic stem cells. Mol. Cell 42, 451–464. doi: 10.1016/j.molcel.2011.04.005
Yamaguchi, S., Hong, K., Liu, R., Shen, L., Inoue, A., Diep, D., et al. (2012). Tet1
controls meiosis by regulating meiotic gene expression. Nature 492, 443–447.
doi: 10.1038/nature11709
Yamaguchi, S., Shen, L., Liu, Y., Sendler, D., and Zhang, Y. (2013). Role of Tet1 in
erasure of genomic imprinting. Nature 504, 460–464. doi: 10.1038/nature12805
Yang, Y. X., Wood, N. W., and Latchman, D. S. (2009). Molecular basis of
Parkinson’s disease. Neuroreport 20, 150–156. doi: 10.1097/WNR.0b013e32831
c50df
Yao, B., Lin, L., Street, R. C., Zalewski, Z. A., Galloway, J. N., Wu, H., et al. (2014).
Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of frag-
ile X-associated tremor/ataxia syndrome. Hum. Mol. Genet. 23, 1095–1107. doi:
10.1093/hmg/ddt504
Yildirim, O., Li, R., Hung, J. H., Chen, P. B., Dong, X., Ee, L. S., et al. (2011).
Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine
marked genes in embryonic stem cells. Cell 147, 1498–1510. doi: 10.1016/j.cell.
2011.11.054
Yin, R., Mao, S. Q., Zhao, B., Chong, Z., Yang, Y., Zhao, C., et al. (2013). Ascorbic
acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA
demethylation in mammals. J. Am. Chem. Soc. 135, 10396–10403. doi: 10.1021/
ja4028346
Zhang, B., Lv, Q., Pu, J., Lei, X., and Mao, Y. (2013). Distribution
of 5-hydroxymethylcytosine in rat brain tissues and the role of 5-
hydroxymethylcytosine in aging and vivo model of Parkinson’s disease.
Mov. Disor. 28(Suppl. 1), 852
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 01 October 2014; accepted: 18 November 2014; published online: 05
December 2014.
Citation: Al-Mahdawi S, Anjomani Virmouni S and Pook MA (2014) The emerging
role of 5-hydroxymethylcytosine in neurodegenerative diseases. Front. Neurosci. 8:397.
doi: 10.3389/fnins.2014.00397
This article was submitted to Neurogenomics, a section of the journal Frontiers in
Neuroscience.
Copyright © 2014 Al-Mahdawi, Anjomani Virmouni and Pook. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | Neurogenomics December 2014 | Volume 8 | Article 397 | 8
